Exploring how a specific protein affects cognitive issues related to COVID-19 in older adults
Investigating the role and therapeutic potential of the alpha5beta1 integrin in risk factors for COVID-19-associated cognitive impairment
This study is looking at how COVID-19 might lead to memory and thinking problems in older adults with vascular dementia, and it will test if a special treatment can help improve their brain function by blocking a specific protein.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Tulane University of Louisiana NIH-funded |
| Lab location | 1 site (New Orleans, United States) |
| Project ID | NIH-10658178 on NIH RePORTER |
What this research studies
This research investigates the connection between vascular dementia and cognitive decline following COVID-19, particularly focusing on the role of the alpha5beta1 integrin protein. The study aims to understand how disruptions in the blood-brain barrier and reduced blood flow in the brain contribute to these cognitive issues. By using a clinically-validated inhibitor, researchers will assess whether blocking this protein can mitigate cognitive impairment in older adults affected by COVID-19. The approach includes both laboratory studies and potential clinical applications to improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are older adults who have experienced cognitive decline or vascular dementia, particularly those who have had COVID-19.
Not a fit: Patients who are younger or do not have a history of cognitive impairment or vascular dementia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies to protect cognitive function in older adults who have experienced COVID-19.
How similar studies have performed: Previous research has shown promising results in targeting similar pathways for cognitive impairment, suggesting potential for success in this novel approach.
Where this research is happening
New Orleans, United States
- Tulane University of Louisiana — New Orleans, United States (Active)
Researchers
- Principal investigator: Bix, Gregory Jaye — Tulane University of Louisiana
- Study coordinator: Bix, Gregory Jaye
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.